

Ref: Akums/Exchange/2026-27/03

April 11, 2026

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Intimation of reaffirmed/ new Credit Rating under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Respected Sir/Mam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the details of the reaffirmed/ new credit rating issued by ICRA Limited (Credit Rating Agency) vide its Report dated April 10, 2026.

Name of the Company	Credit Rating Agency	Type of Instrument	Rating Action
Akums Drugs and Pharmaceuticals Limited	ICRA Limited	Long-term/ short-term fund-based/ non-fund based working capital limits	AA (Stable)/ A1+; reaffirmed
Akums Drugs and Pharmaceuticals Limited	ICRA Limited	Proposed Commercial Paper Programme	A1+; assigned

The report from the credit rating agency is enclosed.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

April 10, 2026

Akums Drugs & Pharmaceuticals Limited: Ratings reaffirmed for bank facilities and assigned for commercial paper programme

Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating action
Long-term – fund-based cash credit	50.00	-	-
Short-term – non-fund based limits	10.00	-	-
Long-term/ short-term fund-based/ non-fund based working capital limits	85.00	85.00	[ICRA]AA (Stable)/[ICRA]A1+; reaffirmed
Proposed commercial paper programme	-	200.00	[ICRA]A1+; assigned
Total	145.00	285.00	

*Instrument details are provided in Annexure I

Rationale

While assigning the credit ratings, ICRA has taken a consolidated view of Akums Drugs & Pharmaceuticals Limited (ADPL) and its key subsidiaries (together referred to as the Akums Group/ ADPL)—Pure & Cure Healthcare Private Limited (PCHPL), Malik Lifesciences Private Limited (MLPL) and Maxcure Nutravedics Limited (MNL), given the common management and significant operational and financial linkages among them.

The reaffirmation of the ratings factor in the Group's established position as a leading contract manufacturer of generic pharmaceutical products in the domestic market, supported by its sizeable manufacturing capacities and wide product portfolio catering to a diversified clientele of leading domestic and multinational pharmaceutical companies and wellness players. The contract development and manufacturing organisation (CDMO) business of ADPL generated a revenue of Rs. 2,533 crore in 9M FY2026 with a 7% YoY growth driven by volume growth of around 11% while price variance remained negative. The CDMO segment is expected to continue to grow over the near to medium term, aided by volume growth in the domestic market and commencement of sales to Europe as part of ADPL's long-term contract with a European customer, valued at EUR 200 million. As part of the agreement, ADPL received an upfront payment of EUR 100 million in Q1 FY2026, which has strengthened its liquidity position.

The ratings also draw comfort from ADPL's comfortable financial profile with a strong liquidity position and healthy capitalisation and coverage indicators owing to its minimal dependence on external debt. It had a total debt (including lease liabilities) of Rs. 90.3 crore as on September 30, 2025, with a total debt/ OPBDITA of 0.2 times. In the absence of the requirement of any major debt-funded capex over the near to medium term, ADPL is likely to sustain its strong financial profile.

The ratings, however, remain constrained by the vulnerability of ADPL's profitability to competitive pressures and raw material price volatility. The company's trade generics and active pharmaceutical ingredient (API) manufacturing businesses have reported consistent operating losses over the years, primarily due to intense competition, limited pricing flexibility and exposure to input cost volatility. ADPL has made sizeable investments in these businesses over the years and the recovery of commensurate returns is likely to be gradual and contingent upon adequate scale up and favourable raw material pricing. ADPL's revenues are also concentrated geographically as exports generated less than 5% of its total revenues over FY2025 and 6M FY2026. However, the expected commencement of sales to Europe and Zambia over CY2027, via the two contracts undertaken by the company, shall help increase its geographical diversification.

ADPL also continues to remain exposed to legal and regulatory risks, including scrutiny by regulatory agencies, product liability matters, inclusion of more drugs under the National List of Essential Medicines (NLEM) and other commercial matters. The company has thus far not disclosed any material developments or potential liabilities with respect to the searches initiated by the Income Tax (IT) department at a few of its offices and manufacturing units, at that of its subsidiaries, and at the residences of few of its employees/key managerial personnel in January 2025. However, ICRA would continue to monitor closely any developments related to this event and take appropriate rating action, if necessary.

The Stable outlook for the long-term rating reflects ICRA's expectation that the company will continue to generate healthy cashflows aided by its strong CDMO business; and coupled with low debt levels, this shall lead to the sustenance of a strong credit profile.

Key rating drivers and their description

Credit strengths

Leading contract manufacturer in generic pharmaceutical industry – ADPL is the largest contract manufacturer catering to the domestic branded generic formulations industry. The company has 14 formulations manufacturing units with a combined production capacity of around 49.6 billion units per annum, having commercialised more than 4,100 formulations across more than 60 dosage forms. In addition, the Group has also been increasing its footprint in the marketing business, with rising presence in exports and branded generics, as well as in the trade generics and API businesses. While the current scale of these businesses is lower than the Group's overall revenues, it has healthy growth opportunities over the long term.

Diversified customer profile, including reputed pharma companies – The Group enjoys good relationships with its customers, including several leading domestic and multinational pharmaceutical and wellness companies. It has a diversified customer base, serving more than 1,400 clients with adequate customer diversification.

Healthy financial profile – ADPL has a healthy financial profile aided by healthy earnings and a strong liquidity position with minimal dependence on external debt. ADPL's revenues grew by 5% YoY to Rs. 3,201.1 crore in 9M FY2025 with an operating profit margin (OPM) of 11.6% and a net profit margin of 5.5%. The revenues and profitability are expected to increase gradually, aided by the commencement of exports to regulatory markets and growth in the domestic business. As on September 30, 2026, it had a total debt (including lease liabilities) of Rs. 90.3 crore against cash and cash equivalents of Rs. 1,654.4 crore. Accordingly, its coverage and capitalisation indicators were healthy with Total Debt/OPBDITA of 0.2 times, interest cover of 4.8 times and total outside liabilities/ tangible net worth (TOL/TNW) of 0.6 times. Moreover, ADPL is likely to sustain a strong financial profile aided by its healthy cash flow generation, continued minimal reliance on external debt and a strong liquidity profile.

Credit challenges

Profitability vulnerable to competitive pressure and raw material price volatility – ADPL's profitability continues to be vulnerable to pricing pressure as it operates in a very competitive industry. However, the contract manufacturing business has generated stable operating profit margins over the past few years. The company's profitability is also exposed to fluctuations in raw material prices, which continue to impact the profitability of its API business.

Low geographical diversity with exports generating limited share of revenues – The Group primarily caters to the domestic market, which has historically generated more than 90-95% of its revenues. However, the company is expected to gradually improve its geographical diversity with expected sales to European markets through its CDMO business and to Zambia through its formulations export business.

Significant investments in various marketing subsidiaries/inorganic acquisitions, returns from which will take time to improve – The Group's flagship company, ADPL, has made significant investments in its marketing subsidiaries and acquisitions (including the API business) over the past few years to diversify its profile and add more growth levers. These subsidiaries have been accepting loans and advances (primarily from the parent entity) to meet their working capital requirements and loss funding. While the branded formulations and formulations export businesses have improved their performance significantly

over the last few years, the trade generics and the API businesses have continued to report operating losses. ADPL continues to invest in these entities for performance recovery. However, any meaningful contribution from these businesses and generation of commensurate returns from these investments are estimated to be gradual.

Liquidity position: Strong

The Group's liquidity position is strong, characterised by healthy cash flow from operations, cash and cash equivalents of Rs. 1,654.4 crore and unutilised working capital limits of around Rs. 450 crore, as on September 30, 2025. ADPL is expected to incur a capex of around Rs. 250 crore per annum between FY2026 and FY2028, primarily towards the development of a manufacturing facility in Zambia and regular replacement and maintenance capex. The capex is likely to be funded through ADPL's existing liquidity and internal accruals. Moreover, ADPL has no long-term debt repayment obligations.

Environment and social risks

Environmental considerations – ADPL does not face any major physical climate risk. However, it remains exposed to tightening environmental regulations regarding the breach of waste and pollution norms, which can lead to an increase in operating costs and new capacity instalment costs. This may also require capital investments to upgrade its effluent treatment infrastructure to reduce its carbon footprint and waste generation.

Social considerations – ADPL faces high industry-wide social risks related to product safety and its associated litigation risks, access to qualified personnel for R&D and process engineering, as well as for maintenance of high manufacturing compliance standards. Further, Government interventions related to price caps/controls also remain a social risk for entities in the pharmaceutical industry.

Rating sensitivities

Positive factors – An increase in the scale of the company along with strengthening of its business risk profile, aided by material diversification in the form of gain in business from exports or a healthy scale-up in revenue and profits from the API and marketing businesses, while maintaining strong credit metrics and healthy liquidity position, would be favourably considered for a long-term rating upgrade.

Negative factors – The ratings could be downgraded in case of a significant decline in revenues and accrual generation or a deterioration in the credit profile and liquidity position, owing to debt-funded capex or a stretch in the working capital cycle. Specific credit metrics that may trigger a rating downgrade would include Total Debt/ OPBDITA of more than 1.0 times on a sustained basis.

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Pharmaceuticals Corporate Credit Rating Methodology
Parent/Group support	Not applicable
Consolidation/Standalone	ICRA has taken a consolidated view of ADPL and its subsidiaries, PCHPL, MLPL and MNL, while assigning the credit ratings, given the common management and significant operational and financial linkages among the entities. For arriving at the ratings, ICRA has considered the consolidated financials of ADPL. The details of its subsidiaries and step-down subsidiaries are listed in Annexure II.

About the company

Incorporated in 2004, ADPL is a leading contract manufacturer of formulations for domestic as well as multinational pharmaceutical and wellness companies in India. ADPL has 12 facilities in Uttarakhand and Himachal Pradesh for its formulations manufacturing business and three units in Punjab and Haryana for its API manufacturing business. These manufacturing units are housed under ADPL and its various subsidiaries. The Group has commercialised more than 4,000 formulations across more than 60 dosage forms.

In FY2020, the company raised Rs. 500 crore from Quadria Capital in exchange for a 15.09% stake, of which Rs. 320.0 crore was infused into the company and the balance was paid to the promoters against sale of shares. The company was listed on the national stock exchanges in August 2024.

Key financial indicators (audited)

Akums Group (consolidated)	FY2024	FY2025	9M FY2026*
Operating income	4,180.7	4,120.9	3,201.1
PAT	0.8	343.8	175.1
OPBDIT/OI	11.6%	11.3%	11.6%
PAT/OI	0.0%	8.3%	5.5%
Total outside liabilities/Tangible net worth (times)	3.7	0.3	-
Total debt/OPBDIT (times)	1.2	0.2	-
Interest coverage (times)	9.6	13.4	5.3

Source: Company, ICRA Research; * Provisional numbers; All ratios as per ICRA's calculations; Amount in Rs. crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Current (FY2027)			Chronology of rating history for the past 3 years					
	Type	Amount Rated	10-Apr-2026	FY2026		FY2025		FY2024	
				Date	Rating	Date	Rating	Date	Rating
Unallocated	Long term/short term	-	-	-	-	09-OCT-2024	[ICRA]AA (Stable)/[ICRA]A1+	-	-
						31-JAN-2025	[ICRA]AA (Stable)/[ICRA]A1+	-	-
Fund based /non fund based limits	Long term/short term	85.00	[ICRA]AA (Stable)/[ICRA]A1+	09-Apr-2025	[ICRA]AA (Stable)/[ICRA]A1+	09-OCT-2024	[ICRA]AA (Stable)/[ICRA]A1+	-	-
						31-JAN-2025	[ICRA]AA (Stable)/[ICRA]A1+	-	-
Fund based - cash credit	Long term	-	-	09-Apr-2025	[ICRA]AA (Stable)	09-OCT-2024	[ICRA]AA (Stable)	08-SEP-2023	[ICRA]AA-(Stable)
						31-JAN-2025	[ICRA]AA (Stable)	-	-
Non fund based limits	Short term	-	-	09-Apr-2025	[ICRA]A1+	09-OCT-2024	[ICRA]A1+	08-SEP-2023	[ICRA]A1+
						31-JAN-2025	[ICRA]A1+	-	-
Term loans	Long term	-	-	-	-	-	-	08-SEP-2023	[ICRA] AA-(Stable)
Fund-based/ non-fund based limits	Long term/short term	-	-	-	-	-	-	08-SEP-2023	[ICRA] AA-(Stable)/[ICRA] A1+
Proposed commercial paper programme	Short term	200.00	[ICRA]A1+	-	-	-	-	-	-

Complexity level of the rated instruments

Instrument	Complexity indicator
Proposed commercial paper programme	Simple
Long-term short-term fund based/ non fund based working capital limits	Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Proposed Commercial Paper Programme	NA	NA	NA	200.00	[ICRA]A1+
NA	Long-term/Short-term – fund-based/non-fund based working capital limits	NA	NA	NA	85.00	[ICRA]AA (Stable)/[ICRA]A1+

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company name	ADPL's Ownership	Consolidation approach
SUBSIDIARIES		
Akumentis Healthcare Limited	91.50%	Full consolidation
Qualymed Pharma Private Limited	100.00%	Full consolidation
Akums Healthcare Limited	100.00%	Full consolidation
Malik Lifesciences (P) Ltd	100.00%	Full consolidation
Maxcure Nutravedics Ltd	100.00%	Full consolidation
Nicholas Healthcare Ltd	100.00%	Full consolidation
Plenteous Pharmaceuticals Ltd	100.00%	Full consolidation
Pure & Cure Healthcare Private Limited	100.00%	Full consolidation
Unosource Pharma Ltd	100.00%	Full consolidation
Upadrish Reserchem LLP	99.93%	Full consolidation
Sarvagunaushdhi Private Limited	100.00%	Full consolidation
STEP DOWN SUBSIDIARIES		
Medibox Pharma Private Limited	100.00%	Full consolidation

Source: ADPL's Annual report for FY2025

Note: ICRA has taken a consolidated view of Akums Drugs & Pharmaceuticals Limited and its subsidiaries – Pure & Cure Healthcare Private Limited, Malik Lifesciences Private Limited and Maxcure Nutravedics Limited.

ANALYST CONTACTS

Jitin Makkar

+01244545368

jitinm@icraindia.com

Kinjal Shah

+91 022 61143400

kinjal.shah@icraindia.com

Deepak Jotwani

+91 124 4545870

deepak.jotwani@icraindia.com

Gaurav Kushwaha

+91 22 61143465

aurav.kushwaha@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.